

Author: Carlsson Tony Reichard Olle Weiland Ola
Publisher: Informa Healthcare
ISSN: 0036-5548
Source: Scandinavian Journal of Infectious Diseases, Vol.33, Iss.11, 2001-11, pp. : 838-842
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
We studied HCV kinetics during the first 84 d of interferon-alpha (IFN) treatment. IFN was administered either at a dose of 3 million units daily for the first 14 d and thereafter 3 times per week (t.i.w.) (induction treatment), or at a dose of 3 million units t.i.w. throughout (standard treatment). No patient had received HCV treatment previously, and all had a pretreatment viral load of <1.2 × 106 IU/ml at screening. Ten patients were given induction treatment and 21 received the standard t.i.w. regimen. Twenty patients were infected with genotype 1. At Day 2, the median HCV RNA level in the induction group was significantly lower compared to that of the standard treatment group. This significant difference persisted during the study period for patients infected with genotype 1, but was not maintained from Day 14 onwards for patients with genotype non-1. At Day 84, 80% (8/10) of patients in the induction group, compared to 16% (3/19) in the standard treatment group, had undetectable (<600 IU/ml) HCV RNA levels (p <0.05). We conclude that induction treatment resulted in a significantly greater decline in HCV RNA levels than standard treatment.
Related content




By Balciuniene Ligita Carlsson Tony Ambrozaitis Arvydas Reichard Olle Weiland Ola
Scandinavian Journal of Infectious Diseases, Vol. 35, Iss. 3, 2003-01 ,pp. :


Effect of interferon‐alpha therapy on hepatitis D virus
HEPATOLOGY, Vol. 61, Iss. 6, 2015-06 ,pp. :




Intervirology, Vol. 48, Iss. 1, 2005-03 ,pp. :